P006 DISCORDANCE OF COMMUNICATION PRIORITIES BETWEEN HEALTHCARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY. (7th February 2019)

• Record Type: Journal Article
• Authors: Rubin, David T; Panaccione, Remo; Kayhan, Cem; Lopez-Sanroman, Antonio; Rubin, Michele; Peyrin-Biroulet, Laurent; Armuzzi, Alessandro; Dubinsky, Marla; Keefer, Laurie; Melmed, Gil; Colombel, Jean-Frederic
• Is Part Of: Inflammatory bowel diseases. Volume 25(2019)Supplement 1
• Page Start: S4
• Page End: S5
• Publication Date: 2019-02-07
• Subjects: Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izy393.009
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: Objective: The Ulcerative Colitis (UC) Narrative is a global survey of patients (pts) and gastroenterology physicians (GIs) aimed at identifying the impact of the disease and comparing and contrasting perceptions of UC burden and management approaches. We describe the prioritization of topics for discussion at routine appointments from pt and GI perspectives, and examine the potential impact of any discordance. Data are presented from 2100 pts and 1254 GIs in Australia, Canada, Finland, France, Germany, Italy, Japan, Spain, the UK, and the USA. Methods: Surveys were conducted online and by phone by The Harris Poll between August 2017 and February 2018. Eligible adult pts with UC (confirmed by endoscopy) were those who had visited a GI in the previous 12 months and had ever received prescription medication for UC. Self-reported medication history was used as a proxy for disease severity, with pts with moderate to severe UC defined as pts who had ever taken immunosuppressants, tumor necrosis factor inhibitors, other biologics, or corticosteroids for >4 of the past 12 months. Pts who had only ever taken 5-aminosalicylates or had a colectomy were excluded. Eligible GIs were those who saw ≥10 UC pts each month (≥5 in Japan), of whom ≥10% were taking a biologic and did not practice in a long-term care facility or hospice. Data are presented from all respondents who consented and completed the survey. Results: Pts were a mean age of 40.8 years (standard deviation [SD] 12.4), 53% were male, and 82% had moderate to severe UC, with 67% considering their UC to be controlled with few to no symptoms. Survey responses showed some overlap between pts and GIs in their priorities for discussion at routine appointments. The top priorities selected for pts were discussions on 'ability to manage symptoms' (32%), 'symptoms/problems experienced since last visit' (29%), 'how to control inflammation' (29%), and 'cancer risk' (24%), while GIs' highest priorities for discussion included 'symptoms since last visit' (53%), 'ability to manage symptoms' (40%), and 'side effects of current treatment' (40%). The greatest discordance between pt and GI prioritization was observed for cancer risk (24% vs 11%), fatigue management (16% vs 5%), emotional impact (13% vs 7%), and new medications (21% vs 15%). Both pts (63%) and GIs (79%) wish they had more time at appointments. Conclusions: Symptom control is a high priority for discussion among pts with UC and GIs, but other topics such as cancer risk, fatigue management, emotional impact, and new medications were viewed as less of a priority for GIs than for pts. GIs need to be mindful of those topics of greatest concern to the pt, and identify ways to discuss topics important to both parties, since shortage of appointment time is a barrier to communication.